Product nameSodium butyrate, Histone deacetylase inhibitor
DescriptionHistone deacetylase inhibitor
Biological descriptionHistone deacetylase inhibitor (IC50 values are 0.3, 0.4 and 0.3 mM for HDAC1, 2 and 7, respectively). Shows no inhibition of HDAC6 and 10. Anticancer activity. Crosses the blood-brain barrier.
Chemical nameSodium butanoate
Storage instructionsStore at Room Temperature. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in water to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Our Abpromise guarantee covers the use of ab120948 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Functional Studies||Use at an assay dependent concentration.|
HeLa cells were incubated at 37°C for 6h with vehicle control (0 µM) and different concentrations of sodium butyrate (ab120948). Increased expression of histone H3 (acetyl K27) (ab4729) in HeLa cells correlates with an increase sodium butyrate concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab4729 at 1 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
HeLa cells were incubated at 37°C for 6h with vehicle control (0 µM) and different concentrations of sodium butyrate (ab120948). Increased expres
ab4729 staining Histone H3 (acetyl K27) in HeLa cells. The cells were incubated with 10mM Sodium butyrate (ab120948) for 6 hours (Treated) or solvent-only for control purposes (Non-treated). Cells were fixed with 100% methanol (5min) and then blocked in 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. The cells were then incubated with ab4729 at 0.5µg/ml and ab7291 at 1µg/ml overnight at +4°C, followed by a further incubation at room temperature for 1h with a anti-rabbit AlexaFluor®488 secondary antibody (ab150077) at 2 μg/ml (shown in green) and a goat anti-mouse AlexaFluor®594 (ab150120) at 2 μg/ml (shown in pseudo colour red). Nuclear DNA was labelled in blue with DAPI. Negative controls: 1– Rabbit primary and anti-mouse secondary antibody; 2 – Mouse primary antibody and anti-rabbit secondary antibody. Controls 1 and 2 indicate that there is no unspecific reaction between primary and secondary antibodies used.
This product has been referenced in:
- Grayson DR et al. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77:126-35 (2010). Read more (PubMed: 19917878) »
- Pajak B et al. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Adv Med Sci 52:83-8 (2007). Read more (PubMed: 18217395) »
- Gurvich N et al. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-86 (2004). Read more (PubMed: 14871841) »
- Guardiola AR & Yao TP Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 277:3350-6 (2002). Read more (PubMed: 11726666) »